

LIPITZ QUARTERLY

Roger C. Lipitz Center for Integrated Health Care

POLICY-DIRECTED RESEARCH TO IMPROVE CARE FOR PERSONS WITH COMPLEX HEALTH NEEDS

SUMMER NEWSLETTER 2021 Stemming the High and Rising Costs of Prescription Drugs



The Roger C. Lipitz Center for Integrated Health Care is pleased to share the newly released Stemming the High and Rising Costs of Prescription Drugs issue brief in this Summer 2021 Lipitz Quarterly Newsletter.

POLICY INITIATIVES AND IMPACT

For over 5 years, faculty at the Roger C. Lipitz Center for Integrated Health Care based in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health have engaged in a multi-disciplinary initiative to understand the landscape and propose solutions to reduce prescription drug spending in America. Collaborating with decision makers and developing policies to reduce prescription drug spending without stifling innovation in the pharmaceutical industry is key. Learn more about how the Center is working with Congress, partnering with states, and liaising with the Federal Administration on policy initiatives.



SELECT PUBLICATIONS

Legislative initiatives are supported and elevated by peer-reviewed publications and detailed modeling led by the Center. Explore select papers authored by Center faculty, which are published in JAMA Network Open, American Journal of Public Health, JAMA Pediatrics, and Health Affairs.



Category in 2008 and 2019 in JAMA Network Open and Affording Genetic <u>Therapies in the Medicaid Program</u> in *JAMA Pediatrics*.

Jeromie Ballreich published Allocation of NIH Funding by Disease



U.S. Pharmaceutical Supply Chain in Public Health Crises in the American Journal of Public Health and Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program in JAMA Network Open.


Mariana P. Socal published <u>Critical Drugs for Critical Care: Protecting the</u>



Part D To Reduce Drug Price Differentials With Other Countries and Ultra-Expensive Drugs and Medicare Part D: Spending And Beneficiary Use Up Sharply in Health Affairs.

So-Yeon Kang published <u>Using External Reference Pricing In Medicare</u>

IN THE MEDIA



skyrocketing cost of many prescription drugs in the U.S. can be blamed primarily on price increases, not expensive new therapies or improvements in existing medications as drug companies frequently claim. He was also mentioned in The Philadelphia Inquirer about the Pennsylvania proposal of a board to investigate increasing drug prices

Gerard Anderson (pictured left) was interviewed on NPR sharing why the

Mariana Socal is quoted in a MedPage Today article about a bill to let Medicare negotiate

drug prices. Jeromie Ballreich is quoted in a Healio article discussing the stability of NIH funding

allocation over time. So-Yeon Kang contributed to an article in Axios highlighting how higher prices drive up

Medicare drug spending.

624 N. Broadway, Baltimore, MD 21205 | 410-614-7910

Roger C. Lipitz Center for Integrated Health Care The Johns Hopkins Bloomberg School of Public Health

Share this email:







Got this as a forward? Sign up to receive our future emails. View this email online.

624 North Broadway, Room 692 Baltimore, MD | 21205 US

This email was sent to To continue receiving our emails, add us to your address book. emma